E-LIB Suche - Ergebnisse für: Anna V. Tinker

1

Targeting HER2-mutant metastatic cervical cancer with nerat..:

Friedman, Claire F. ; D'Souza, Anishka ; Bello Roufai, Diana...
Gynecologic Oncology. 181 (2024) - p. 162-169 , 2024

Link: https://doi.org/10.1016/..

2

Efficacy and safety of niraparib in patients aged 65 years ..:

Valabrega, Giorgio ; Pothuri, Bhavana ; Oaknin, Ana...
Gynecologic Oncology. 187 (2024) - p. 128-138 , 2024

Link: https://doi.org/10.1016/..

3

A plain language summary of results from the GARNET study o..:

Oaknin, Ana ; Gilbert, Lucy ; Tinker, Anna V...
Future Oncology. 19 (2023) 25 - p. 1709-1714 , 2023

Link: https://doi.org/10.2217/..

4

CD8 + T cell infiltration is associated with improved survi..:

Guo, Nancy ; Yang, Aijun ; Farooq, Fabiha Binte...
Scientific Reports. 13 (2023) 1 - p. , 2023

Link: https://doi.org/10.1038/..

5

A Phase Ib Study Assessing the Safety, Tolerability, and Ef..:

Bauer, Todd M. ; Moore, Kathleen N. ; Rader, Janet S....
Targeted Oncology. 18 (2023) 4 - p. 517-530 , 2023

Link: https://doi.org/10.1007/..

6

Fighting resistance: post-PARP inhibitor treatment strategi..:

Veneziani, Ana C. ; Scott, Clare ; Wakefield, Matthew J...
Therapeutic Advances in Medical Oncology. 15 (2023) - p. 175883592311576 , 2023

Link: https://doi.org/10.1177/..

7

A rapidly evolving landscape: immune checkpoint inhibitors ..:

Tinker, Anna V. ; Dhani, Neesha C. ; Ghatage, Prafull...
Therapeutic Advances in Medical Oncology. 15 (2023) - p. 175883592311576 , 2023

Link: https://doi.org/10.1177/..

8

Survival and modelled cancer antigen-125 ELIMination rate c..:

Corbaux, Pauline ; You, Benoit ; Glasspool, Rosalind M....
European Journal of Cancer. 191 (2023) - p. 112966 , 2023

Link: https://doi.org/10.1016/..

9

Safety, Efficacy, and Biomarker Analyses of Dostarlimab in ..:

Oaknin, Ana ; Pothuri, Bhavana ; Gilbert, Lucy...
Clinical Cancer Research. 29 (2023) 22 - p. 4564-4574 , 2023

Link: https://doi.org/10.1158/..

10

Safety and antitumor activity of dostarlimab in patients wi..:

Oaknin, Ana ; Gilbert, Lucy ; Tinker, Anna V...
Journal for ImmunoTherapy of Cancer. 10 (2022) 1 - p. e003777 , 2022

Link: https://doi.org/10.1136/..

11

Results of the phase I CCTG IND.231 trial of CX-5461 in pat..:

Hilton, John ; Gelmon, Karen ; Bedard, Philippe L....
Nature Communications. 13 (2022) 1 - p. , 2022

Link: https://doi.org/10.1038/..

12

Corrigendum to "Low-grade serous carcinoma (LGSC): A Canadi..:

Scott, Stephanie A. ; Fernandez, Marta Llaurado ; Kim, Hannah...
Gynecologic Oncology. 167 (2022) 2 - p. 399 , 2022

Link: https://doi.org/10.1016/..

13

Cervical cancer patient reported gastrointestinal outcomes:..:

Urban, Ryan ; Wong, Justin ; Lim, Peter...
Journal of Gynecologic Oncology. 33 (2022) 5 - p. , 2022

Link: https://doi.org/10.3802/..

14

Treatment and outcomes in undifferentiated and dedifferenti..:

Hamilton, Sarah Nicole ; Tinker, Anna V. ; Kwon, Janice...
Journal of Gynecologic Oncology. 33 (2022) 3 - p. , 2022

Link: https://doi.org/10.3802/..

15

A Pan-Canadian Consensus Statement on First-Line PARP Inhib..:

Tinker, Anna V. ; Altman, Alon D. ; Bernardini, Marcus Q....
Current Oncology. 29 (2022) 6 - p. 4354-4369 , 2022

Link: https://doi.org/10.3390/..